<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7127009\results\search\testTrace\results.xml">
  <result pre="Elsevier Ltd. S0896-8411(20)30055-X doi: 10.1016/j.jaut.2020.102442102442 : Article Recommendations for coronavirus" exact="infection" post="in rheumatic diseases treated with biologic therapy CeribelliAngelaa1MottaFrancescab1De SantisMariaaAnsariAftab"/>
  <result pre="as anti-CD200 and anti-PD1 could have a role in the" exact="treatment" post="of CoViD-19. Rheumatic disease patients taking immunosuppressive drugs should"/>
  <result pre="drugs should be recommended to maintain the chronic therapy, prevent" exact="infection" post="by avoiding social contacts and pausing immunosuppressants in case"/>
  <result pre="CoViD-19. â€¢Recommendations for rheumatic disease patients include the prevention of" exact="infection" post="by avoiding social contacts. â€¢Patients should also continue their"/>
  <result pre="illness in the Hubei province. Since these earliest reports, this" exact="infection" post="has spread in many countries worldwide with a significant"/>
  <result pre="spread in many countries worldwide with a significant rate of" exact="infection" post="in Italy that currently accounts for more than 110,000"/>
  <result pre="inhibitors and tocilizumab have been proposed and/or used for the" exact="treatment" post="of select patients who develop a frequently fatal clinical"/>
  <result pre="hosts [1].&quot;&quot; Person-to-person transmission has already been established for SARS-CoV2" exact="infection" post="and reasoned to be mediated by respiratory droplets. The"/>
  <result pre="at a significantly higher risk and higher mortality. The CoViD-19" exact="infection" post="is suspected when patients develop fever, cough, myalgia and"/>
  <result pre="response seem to have the potential to interfere with CoViD-19" exact="infection" post="and their potential benefit is being studied in patients"/>
  <result pre="therefore a promising drug for both the prevention and the" exact="treatment" post="of CoViD-19, with low risk of toxicity [9]. These"/>
  <result pre="patients. Hydroxychloroquine is thus being used in Italy for the" exact="treatment" post="of CoViD-19 patients despite the absence of efficacy data"/>
  <result pre="in patients with severe compared to uncomplicated SARS or MERS" exact="infection" post="[10,11]. Recent preliminary data from China reported high plasma"/>
  <result pre="and other autoimmune diseases, has been used and approved for" exact="treatment" post="of a variety of clinical conditions that include CRS."/>
  <result pre="cells and patients have increased serum IL-1Î² [14]. Another potential" exact="treatment" post="under evaluation for SARS-CoV2 related acute respiratory disease is"/>
  <result pre="in plasmacytoid dendritic cells of a mouse model of coronavirus" exact="infection" post="[20] and to down-modulate macrophage activation [21]. Interestingly, the"/>
  <result pre="Interestingly, the inhibition of CD200-CD200R1 has positive effects on coronavirus" exact="infection" post="[19,20,22], restoring IFN production and increasing virus clearance. Checkpoint"/>
  <result pre="inhibitory antibody targeting of CD200 has been tested for the" exact="treatment" post="of human cancer [19], thus suggesting the intriguing possibility"/>
  <result pre="intriguing possibility to use currently available checkpoint inhibitors for the" exact="treatment" post="of CoViD-19. A trial with another checkpoint inhibitor, anti-PD1,"/>
  <result pre="are measures such as early recognition of the problem, strict" exact="infection" post="control and identification of infected patients, isolation measures, inclusion"/>
  <result pre="the problem, strict infection control and identification of infected patients," exact="isolation" post="measures, inclusion and formation of new medical and sanitary"/>
  <result pre="CoViD-19 patients and to decrease the risk of acquiring this" exact="infection" post="in particular in rheumatic patients undergoing immunosuppressive therapies (Table"/>
  <result pre="in order to evaluate specific clinical needs. In fact, the" exact="infection" post="risk in rheumatic diseases such as rheumatoid arthritis is"/>
  <result pre="due to therapy discontinuation would confer a higher risk of" exact="infection" post="[23]. Table 1 Recommendations proposed for rheumatic diseases during"/>
  <result pre="during CoViD-19 pandemic. Table 1 1- Do not discontinue immunosuppressive" exact="treatment" post="2- Follow the recommendations for infection prevention suggested by"/>
  <result pre="Do not discontinue immunosuppressive treatment 2- Follow the recommendations for" exact="infection" post="prevention suggested by the Italian Ministry of Health, in"/>
  <result pre="the same reason, rheumatic patients on long term oral glucocorticoid" exact="treatment" post="should not only never stop these abruptly but in"/>
  <result pre="severe pneumonia cases, their availability must be guaranteed for the" exact="treatment" post="of rheumatic patients who are using these compounds. If"/>
  <result pre="exception is hydroxychloroquine, which may have therapeutic potential for CoViD-19" exact="infection" post="and should therefore not be stopped in patients who"/>
  <result pre="changing daily and we still have no knowledge about the" exact="infection" post="rate and course of CoViD-19 in rheumatologic conditions. Therefore,"/>
  <result pre="registry is strongly encouraged to understand the impact of the" exact="infection" post="on specific rheumatic diseases or treatments and the risk"/>
  <result pre="tropismJ. Virol.92242018e01504e0151830258004 8GaoJ.TianZ.BreakthroughYang X.Chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studiesBiosci Trends2020 9YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.In"/>
  <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect."/>
  <result pre="and dendritic cellsJ. Virol.837200930393048Epub 2008/11/1219004938 12LeR.Q.LiL.YuanW.ShordS.S.NieL.HabtemariamB.A.FDA approval summary: tocilizumab for" exact="treatment" post="of chimeric antigen receptor T cell-induced severe or life-threatening"/>
  <result pre="2020 novel coronavirus epidemic in ChinaJ. Autoimmun.202010243432143990 15RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory diseaseLancet (London, England)395102232020e30e31Epub 2020/02/04 16ChannappanavarR.FehrA.R.VijayR.MackM.ZhaoJ.MeyerholzD.K.Dysregulated"/>
  <result pre="in induction of type I interferonInt. Immunopharm.1172011794801Epub 2011/01/31 23JaniM.BartonA.HyrichK.Prediction of" exact="infection" post="risk in rheumatoid arthritis patients treated with biologics: are"/>
 </snippets>
</snippetsTree>
